EU opens first probe into abusive drug patent filings
The European Commission is investigating whether Teva Pharmaceuticals unlawfully delayed the entry of generic drugs to treat multiple sclerosis through patent litigation and a disparaging communications campaign that discredited its competitors.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10